WILEX is a biopharmaceutical company and develops drugs based on antibodies and small molecules with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. WILEX’ aim is to help oncologists administer targeted treatments to carefully diagnosed patients and to enhance patients' quality of life.


Latest News

14.04.2014: WILEX published 3-Month Financial Report 2014....More

10.04.2014: WILEX plans capital reduction....More

Seite gelesen: 129904 | Heute: 236